Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp Receives Approval For PERIMOUNT Mitral Heart Valve In China


Wednesday, 28 Nov 2012 09:00am EST 

Edwards Lifesciences Corp announced that it has received approval from China's State Food and Drug Administration (SFDA) for its Carpentier-Edwards PERIMOUNT Mitral Heart Valve, a replacement heart valve made of bovine pericardial tissue. Designed for the treatment of mitral valve disease, the PERIMOUNT Mitral Heart Valve was introduced into clinical use in 1984 and has demonstrated long-term endurance, as reported in numerous peer-reviewed studies. The valve is treated with the Carpentier-Edwards ThermaFix process, the only anti-calcification tissue treatment that targets both major calcium binding sites that lead to tissue calcification. Edwards' family of PERIMOUNT pericardial valves have been the world's most frequently implanted valves for more than 30 years. 

Company Quote

103.39
1.24 +1.21%
4:01pm EDT